Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908075 | 0.80 | ACP1 (0.48) | DRD2CYP3A4CYP2D6CYP2C9ADORA1 | |
| SCHEMBL2902338 | 0.80 | ELANE (0.39) | ROCK2ROCK1HCRTR1HCRTR2GLS | |
| SCHEMBL2905375 | 0.78 | ACP1 (0.42) | DRD2CYP3A4CYP2D6CYP2C9ADORA1 | |
| SCHEMBL2908507 | 0.78 | MGLL (0.40) | DRD2CYP3A4CYP2D6HCRTR1HCRTR2 | |
| SCHEMBL1616378 | 0.77 | HCRTR1 (0.35) | HCRTR1HCRTR2GLS | |
| SCHEMBL2901732 | 0.74 | EGFR (0.41) | ADORA1HCRTR1HCRTR2 | |
| SCHEMBL2904724 | 0.74 | HCRTR1 (0.33) | TTBK1TTBK2ROCK2ROCK1HCRTR1 | |
| SCHEMBL2901477 | 0.74 | BRD4 (0.32) | TTBK1TTBK2HCRTR1HCRTR2 | |
| SCHEMBL2904343 | 0.74 | BTK (0.36) | DRD2HCRTR1HCRTR2BTKJAK2 | |
| SCHEMBL2906836 | 0.73 | TSHR (0.40) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | claimed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | claimed |
| EP-2076495-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | claimed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | claimed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | claimed |
| EP-1479386-A1 | Use of isoquinoline-derivatives for treating and preventing pigmentary disorders | Switch Biotech Aktiengesellschaft (DE) | 2004-11-24 | — | — | EP | claimed |
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-0956865-B2 | MEDICINES COMPRISING Rho KINASE INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-08-18 | — | — | EP | disclosed |
| EP-2076495-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | disclosed |
| US-6218410-B1 | ADMINISTERING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF A RHO KINASE INHIBITOR COMPRISING AMIDE COMPOUND FOR INHIBITING RHO KINASE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
| US-5747507-A | MYOCARDIAL DISEASE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1998-05-05 | — | — | US | disclosed |
| EP-0654266-A1 | CARDIAC PROTECTIVE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0187371-B1 | SUBSTITUTED ISOQUINOLINESULFONYL COMPOUNDS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1991-06-19 | — | — | EP | disclosed |
| US-4678783-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVES, ARTERIOSCLEROSIS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1987-07-07 | — | — | US | disclosed |
| EP-0187371-A2 | Substituted isoquinolinesulfonyl compounds | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | AR, ADRA2C, RCC2 | MTNR1A 97/4885DRD2 148/4885TTBK1 1539/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | MTNR1A 854/4885DRD2 4632/4885TTBK1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.